ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 

Novel accreditation of European haemophilia treatment and gene therapy centres

1University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, 2Sahlgrenska University Hospital, Gothenburg, Vastra Gotaland, Sweden, 3Department of Pediatric Hematology, Emma Children’s Hospital, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Amsterdam, the Netherlands; Department of Molecular Hematology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands, Amsterdam, Noord-Holland, Netherlands, 4Vivantes Klinikum im Friedrichshain, Berlin, Berlin, Germany, 5Goethe University Hospital, Frankfurt, Hessen, Germany, 6East Kent Hospitals University NHS Trust, Faculty of Health and Wellbeing, Canterbury Christ Church University, Canterbury, England, United Kingdom, 7Children’s Health Ireland at Crumlin, Dublin, Dublin, Ireland, 8European Haemophilia Consortium, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 9European Haempophilia Consortium, Montijo, Setubal, Portugal, 10Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Università degli Studi di Milano, Department of Pathophysiology and Transplantation, and Fondazione Luigi Villa, Milan, Italy., Milan, Lombardia, Italy

Abstract Number: PB1127

Meeting: ISTH 2022 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Background: The international accreditation of haemophilia centres in Europe is run by the EAHAD and EHC since 2013. The centres are designated as European Haemophilia Comprehensive Care Centres (EHCCC) or European Haemophilia Treating Centres (EHTC), based on the specific requirements which evaluate centres’ ability to provide care for patients with haemophilia and allied disorders.

Aims: The development of a novel accreditation for gene therapy and other novel treatment approaches for management of haemophilia by EAHAD and EHC.

Methods: To facilitate the realization of these changes, EAHAD, in collaboration with EHC, has taken the steps to define necessary measures to safeguard quality and improvement of bleeding disorders care throughout Europe, to build a novel model for implementation of gene therapy and to provide a new Auditing and Certification protocol.

Results: The haemophilia centres are organized to offer multi-disciplinary integrated comprehensive care and equal access to all treatment possibilities, including gene therapy, to all patients. A tight network of centres structured along a hub-and-spoke-model, will address all aspects of gene therapy, from dosing, surveillance of the immediate post-infusion period, to the long-term follow-up. We are presently designing the content and logistics of the multidisciplinary Auditing and Certification procedures and expect to start with our auditing process in 2023.

Conclusion(s): The new EAHAD audit and accreditation process has a challenging task to help haemophilia centres to improve the delivery of care by multi-disciplinary integrated comprehensive care model and equal access to all novel therapies, including gene therapy as well as multidisciplinary services to all patients.

To cite this abstract in AMA style:

Boban A, Baghaei Borzabadi F, Fijnvandraat K, Klamroth R, Miesbach W, Stephensen D, Kavanagh M, Noone D, Crato M, Peyvandi F. Novel accreditation of European haemophilia treatment and gene therapy centres [abstract]. https://abstracts.isth.org/abstract/novel-accreditation-of-european-haemophilia-treatment-and-gene-therapy-centres/. Accessed September 29, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/novel-accreditation-of-european-haemophilia-treatment-and-gene-therapy-centres/